Role of Uremic Toxins in Early Vascular Ageing and Calcification

Nikolaos C Kyriakidis1, Gabriela Cobo2, Lu Dai3

  • 1One Health Research Group, Faculty of Medicine, Universidad de Las Américas (UDLA), Antigua Vía a Nayón, Quito EC170124, Ecuador.

Toxins
|January 6, 2021
PubMed

Insights

Uremic toxins in chronic kidney disease (CKD) cause vascular damage, leading to vascular calcification (VC) and early vascular aging (EVA). This review updates understanding of these processes and discusses potential therapeutic targets.

Area of Science:

  • Nephrology
  • Cardiovascular Medicine
  • Toxicology

Background:

  • Advanced chronic kidney disease (CKD) leads to uremic toxin accumulation, impairing cellular functions and causing chronic inflammation.
  • Uremic toxins are linked to vascular smooth muscle cell (VSMC) alterations, promoting vascular calcification (VC) and early vascular aging (EVA).
  • These vascular complications contribute significantly to the high cardiovascular mortality observed in CKD patients.

Purpose of the Study:

  • To provide an updated overview of the pathophysiology and mediators involved in VC and EVA induced by uremic toxins.
  • To discuss the clinical impact of uremic toxin-mediated vascular damage.
  • To explore potential therapeutic strategies for preventing or mitigating these harmful effects.

Main Methods:

  • Literature review and synthesis of current research on uremic toxins and vascular pathology.
  • Analysis of pathophysiological mechanisms underlying vascular calcification and early vascular aging in CKD.
  • Discussion of clinical implications and emerging therapeutic targets.

Main Results:

  • Uremic toxins disrupt biological functions, leading to inflammation and tissue damage.
  • Specific toxins contribute to VSMC changes, driving VC and EVA.
  • These vascular changes are key drivers of cardiovascular risk in CKD.

Conclusions:

  • Understanding the role of uremic toxins in VC and EVA is crucial for managing cardiovascular risk in CKD.
  • Targeting uremic toxins and their downstream effects offers potential therapeutic avenues.
  • Further research into therapeutic targets could improve outcomes for CKD patients.

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
353
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
356
Urinary Tract Calculi I: Introduction01:28

Urinary Tract Calculi I: Introduction

Renal calculi, or kidney stones, are solid deposits of minerals and salts formed inside the kidneys. In medical terminology, "calculus" refers to the stone itself, while "lithiasis" describes the process of stone formation. Depending on their location within the urinary system, these stones may be classified as either urolithiasis, when situated within the urinary tract, or nephrolithiasis, when located within the kidneys. Each term signifies the specific impact of the stone.Predisposition...
229
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
147
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
559
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
191